全文获取类型
收费全文 | 29676篇 |
免费 | 3557篇 |
国内免费 | 1038篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 1141篇 |
妇产科学 | 139篇 |
基础医学 | 2093篇 |
口腔科学 | 94篇 |
临床医学 | 2825篇 |
内科学 | 3912篇 |
皮肤病学 | 187篇 |
神经病学 | 194篇 |
特种医学 | 673篇 |
外国民族医学 | 1篇 |
外科学 | 11548篇 |
综合类 | 4607篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 881篇 |
眼科学 | 26篇 |
药学 | 2365篇 |
14篇 | |
中国医学 | 2986篇 |
肿瘤学 | 564篇 |
出版年
2024年 | 100篇 |
2023年 | 777篇 |
2022年 | 902篇 |
2021年 | 2149篇 |
2020年 | 1553篇 |
2019年 | 1640篇 |
2018年 | 1487篇 |
2017年 | 1474篇 |
2016年 | 1479篇 |
2015年 | 1483篇 |
2014年 | 2296篇 |
2013年 | 2319篇 |
2012年 | 1597篇 |
2011年 | 1786篇 |
2010年 | 1486篇 |
2009年 | 1319篇 |
2008年 | 1332篇 |
2007年 | 1210篇 |
2006年 | 1104篇 |
2005年 | 942篇 |
2004年 | 810篇 |
2003年 | 693篇 |
2002年 | 591篇 |
2001年 | 553篇 |
2000年 | 369篇 |
1999年 | 309篇 |
1998年 | 276篇 |
1997年 | 217篇 |
1996年 | 234篇 |
1995年 | 203篇 |
1994年 | 191篇 |
1993年 | 152篇 |
1992年 | 152篇 |
1991年 | 146篇 |
1990年 | 107篇 |
1989年 | 114篇 |
1988年 | 79篇 |
1987年 | 81篇 |
1986年 | 65篇 |
1985年 | 65篇 |
1984年 | 71篇 |
1983年 | 39篇 |
1982年 | 52篇 |
1981年 | 49篇 |
1980年 | 33篇 |
1979年 | 45篇 |
1978年 | 33篇 |
1977年 | 29篇 |
1976年 | 26篇 |
1975年 | 18篇 |
排序方式: 共有10000条查询结果,搜索用时 242 毫秒
21.
22.
23.
24.
AbstractBackground: Approximately, 30–40% of patients experienced hearing loss under regular hemodialysis.Objective: This study reviewed our experience on treating acute hearing loss in patients under regular hemodialysis over the past two decades.Methods: Twenty-six patients having acute hearing loss under hemodialysis were divided into two groups based on their etiologies. Sixteen patients (16 ears) with sudden sensorineural hearing loss (SSHL) were assigned to Group A and 10 patients (13 ears) with endolymphatic hydrops (EH) were assigned to Group B.Results: No significant difference was noted between Groups A and B, regardless of hemodialysis duration, clinical manifestation, underlying systemic diseases, blood examination, and vestibular test battery. In contrast, serum osmolality was significantly lower in Group B (292?±?11 mOsm/kg) than in Group A (310?±?11 mOsm/kg). Furthermore, Group B (40?±?14?dB) had better mean hearing level than Group A (87?±?21?dB) in the initial audiogram, and a higher hearing improvement rate (69%) than Group A (19%).Conclusions and significance: Both SSHL and EH are major causes for precipitating acute hearing loss in hemodialysis patients. Compared to SSHL, the less deteriorated MHL and lower serum osmolality in EH provide two clues for differentiating acute hearing loss in hemodialysis patients. 相似文献
25.
26.
Lesley A. Inker Morgan E. Grams Andrew S. Levey Josef Coresh Massimo Cirillo John F. Collins Ron T. Gansevoort Orlando M. Gutierrez Takayuki Hamano Gunnar H. Heine Shizukiyo Ishikawa Sun Ha Jee Florian Kronenberg Martin J. Landray Katsuyuki Miura Girish N. Nadkarni Carmen A. Peralta Dietrich Rothenbacher Mark Woodward 《American journal of kidney diseases》2019,73(2):206-217
27.
老年高血压病以肾气亏虚为主要病机,具有特殊的发病基础、临床症状、传变规律和预后。以"治未病"思想为指导,在老年高血压病发生、发展、预后的各个阶段进行提前干预,有利于扶助正气,增强抗病能力,延缓病情进展。具体而言,未病之时,应通过调整生活方式、服用中药保养和培补肾气,做到未病先防。已病之时,既病防变,阴阳俱虚者,治以补益肾气,方选肾气丸加减;肾阴虚者,治以滋阴补肾,方选左归丸合天麻钩藤饮加减;肾阳虚者,治以温补肾阳,方选右归丸加减。疾病初愈之时,继续以中药补肾虚、调气血,同时避免六淫邪气与情志内伤对机体的损害,以防疾病复发。 相似文献
28.
目的:观察综合疗法治疗慢性肾脏病(CKD)4~5期脾肾亏虚证的效果。方法:将CKD4~5期脾肾亏虚证患者62例随机分为2组,其中治疗组31例,对照组30例(剔除1例)。对照组予基础治疗合中药、骨化三醇及碳酸钙D3片治疗,治疗组予基础治疗合中药、骨化三醇及益肾泄浊汤保留灌肠治疗,观察时间为4周。比较2组血肌酐(Scr)、肾小球滤过率(e GFR)、尿素氮(BUN)、血钙、血磷、碱性磷酸酶(ALP)、甲状旁腺激素(i PTH)及中医证候疗效。结果:中医证候总有效率治疗组为83.87%(26/31),对照组为73.33%(22/30),组间比较,差异有统计学意义(P<0.05);2组Scr、e GFR、BUN、血磷治疗前后组内比较及治疗后组间比较,差异均有统计学意义(P<0.01或P<0.05);2组血钙、i PTH、ALP治疗前后组内比较,差异均有统计学意义(P<0.01),但治疗后组间比较,差异无统计学意义(P>0.05)。结论:综合疗法治疗慢性肾脏病4~5期脾肾亏虚证效果确切,安全可靠。 相似文献
29.
三焦作为六腑之一,是通行水、气和火的通路,与肾具有密切的生理病理性联系。三焦失调是引起慢性肾脏病(chronic kidney disease,CKD)肾阳亏虚、气机逆乱,以及痰湿、血瘀、浊毒等病理产物形成的重要病机,通调三焦法则需贯穿CKD治疗全过程。通调三焦水道的关键在于宣肺利水、淡渗利湿,通调三焦气道的关键在于和解少阳、调畅气机,通调三焦火道的关键在于温补脾肾。三焦调畅,则肺、脾、肾功能正常,气、血、水运行协调,有利于延缓CKD进展。 相似文献
30.
Due to the optimal results obtained in kidney transplantation and to the lack of interest of the industries, new innovative drugs in kidney transplantation are difficult to be encountered. The best strategy to find the new drugs recently developed or under development is to search in the sections of kidney trans plantation still not completely covered by the drugs on the market. These unmet needs are the prevention of delayed graft function (DGF), the protection of the graft over the long time and the desensitization of preformed anti human leukocyte antigen antibodies and the treatment of the acute antibody-mediated rejection. These needs are particularly relevant due to the expansion of some kind of kidney transplantation as transplantation from non-heart beating donor and in the case of antibody-incompatible grafts. The first are particularly exposed to DGF, the latter need a safe desensitization and a safe treatments of the antibody mediated rejections that often occur. Particular caution is needed in treating these drugs. First, they are described in very recent studies and the follow-up of their effect is of course rather short. Second, some of these drugs are still in an early phase of study, even if in well-conducted randomized controlled trials. Particular caution and a careful check need to be used in trials launched 2 or 3 years ago. Indeed, is always necessary to verify whether the study is still going on or whether and why the study itself was abandoned. 相似文献